Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.39 |
| ▸ | TTK | P33981 | 7/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9451618 | 0.79 | ADORA2A (0.37) | LRRK2JAK2NUDT1DYRK1AADORA2A | |
| SCHEMBL30974876 | 0.74 | PDPK1 (0.37) | PDPK1LRRK2DYRK1AADORA2AADORA1 | |
| SCHEMBL9451673 | 0.72 | DYRK1A (0.35) | LRRK2DYRK1A | |
| SCHEMBL27393525 | 0.72 | DYRK1A (0.44) | PDPK1LRRK2DYRK1AADORA2AADORA1 | |
| SCHEMBL16612806 | 0.72 | EGFR (0.41) | PDPK1LRRK2TTKDYRK1AADORA2A | |
| SCHEMBL7958023 | 0.70 | HRH4 (0.45) | PDPK1JAK2DYRK1AADORA2AADORA1 | |
| SCHEMBL16446295 | 0.70 | PDPK1 (0.39) | PDPK1LRRK2TTKDYRK1AADORA2A | |
| SCHEMBL4016987 | 0.68 | MAPT (0.39) | PDPK1LRRK2DYRK1AADORA2AADORA1 | |
| SCHEMBL23313862 | 0.67 | NUDT1 (0.41) | NUDT1DYRK1AADORA2AADORA1 | |
| SCHEMBL5925913 | 0.66 | LRRK2 (0.40) | PDPK1LRRK2TTKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0567223-A1 | Glutamic acid derivatives as antineoplastic agents | ELI LILLY AND COMPANY (US) | 1993-10-27 | — | — | EP | disclosed |
| US-5196424-A | Antitumor | ELI LILLY AND COMPANY (US) | 1993-03-23 | — | — | US | disclosed |